πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 750 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12139528

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12129476

Methods for measuring the potency of AADC viral vectors

VOYAGER THERAPEUTICS, INC. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128092

Lyophilized factor IX formulations

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121567

Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase usin

Regents of the University of Minnesota Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115166

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116606

Complement factor I-related compositions and methods

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12104163

Adeno-associated virus vectors for treatment of Rett syndrome

Sarepta Therapeutics, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091675

Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12077506

Indane derivatives as hypoxia inducible factor-2(Ξ±) inhibitors

NIKANG THERAPEUTICS, INC. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12077772

Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-o

The Board of Regents of the University of Texas System Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12071632

Chimeric vectors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12071468

Purification of Factor VIII subspecies

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12068729

Anti-factor XII/XIIa antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12060566

Self-inactivating lentiviral vector comprising a FOXP3 expression cassette

The Regents of the University of California Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054517

Myeloid differentiation factor 2 (MD2) signaling and modulation

The Regents of the University of California Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049630

Factor XII (F12) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12016932

Gene editing for hemophilia A with improved factor VIII expression

CRISPR THERAPEUTICS AG Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018261

Compounds and methods for modulating factor XII

Ionis Pharmaceuticals, Inc. Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018027

Macrocyclic derivatives acting as XIa factor inhibitor

China Resources Biopharmaceutical Company Limited Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018259

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibito

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012438

Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and the

The United States of America, as represented by the Secretary, Health and Human Services Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006355

Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory f

The Regents of the University of California Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981912

Adeno associated virus vectors for the treatment of hunter disease

Takeda Pharmaceutical Company Limited Β· Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11976293

Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies

The Regents of the University of California Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted